AVIR Q4 2024 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$104,000

Operating Income

-$39M

Net Income

-$34M

EPS (Diluted)

$-0.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$465M

Total Liabilities

$26M

Stockholders' Equity

$439M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$104,000	-$104,000	+0.0%
Operating Income	-$39M	-$47M	+16.2%
Net Income	-$34M	-$39M	+14.4%